氯沙坦及其活性代谢物EXP3174在伊朗健康受试者中的药代动力学 - Suppr

Suppr

超能文献

Pharmacokinetics of Losartan and its Active Metabolite EXP3174 in Healthy Iranian Subjects.

作者信息

Amini Hossein, Ahmadiani Abolhassan, Moazenzadeh Maryam

机构信息

Laboratory of Bioanalysis, Neuroscience Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Clin Drug Investig. 2004;24(10):619-23. doi: 10.2165/00044011-200424100-00008.

DOI:10.2165/00044011-200424100-00008

PMID:17523724

Abstract

摘要

相似文献

Pharmacokinetics of Losartan and its Active Metabolite EXP3174 in Healthy Iranian Subjects.

Clin Drug Investig. 2004;24(10):619-23. doi: 10.2165/00044011-200424100-00008.

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.

Clin Pharmacol Ther. 1995 Dec;58(6):641-9. doi: 10.1016/0009-9236(95)90020-9.

Evaluation of [(11)C]methyl-losartan and [(11)C]methyl-EXP3174 for PET imaging of renal AT1receptor in rats.

Nucl Med Biol. 2015 Nov;42(11):850-7. doi: 10.1016/j.nucmedbio.2015.06.012. Epub 2015 Jun 30.

Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.

Eur J Clin Pharmacol. 2003 Nov;59(8-9):589-92. doi: 10.1007/s00228-003-0664-5. Epub 2003 Sep 19.

The effect of tripterygium glucoside tablet on pharmacokinetics of losartan and its metabolite EXP3174 in rats.

Biomed Chromatogr. 2017 Oct;31(10). doi: 10.1002/bmc.3973. Epub 2017 Apr 24.

Influence of compound danshen tablet on the pharmacokinetics of losartan and its metabolite EXP3174 by liquid chromatography coupled with mass spectrometry.

Biomed Chromatogr. 2013 Sep;27(9):1219-24. doi: 10.1002/bmc.2930. Epub 2013 May 30.

Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus.

Res Commun Mol Pathol Pharmacol. 1998 Aug;101(2):147-58.

Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.

Drug Metab Dispos. 1995 Feb;23(2):285-9.

The physicochemical properties, in vitro metabolism and pharmacokinetics of a novel ester prodrug of EXP3174.

Mol Pharm. 2010 Dec 6;7(6):2132-40. doi: 10.1021/mp100166c. Epub 2010 Oct 1.

Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan.

Pharmacology. 1996 Jan;52(1):25-9. doi: 10.1159/000139357.

引用本文的文献

Allisartan ameliorates vascular remodeling through regulation of voltage-gated potassium channels in hypertensive rats.

BMC Pharmacol Toxicol. 2021 Jun 9;22(1):33. doi: 10.1186/s40360-021-00498-7.

Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension.

Medicine (Baltimore). 2019 Mar;98(12):e14907. doi: 10.1097/MD.0000000000014907.

本文引用的文献

Allele frequency of CYP2C9 gene polymorphisms in Iran.

Thromb Haemost. 2002 Nov;88(5):874-5.

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.

Clin Pharmacol Ther. 2002 Jan;71(1):89-98. doi: 10.1067/mcp.2002.121216.

Role of CYP2C9 polymorphism in losartan oxidation.

Drug Metab Dispos. 2001 Jul;29(7):1051-6.

Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection.

Int J Pharm. 2000 Aug 25;204(1-2):17-22. doi: 10.1016/s0378-5173(00)00453-1.

The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers.

J Clin Pharmacol. 1999 Apr;39(4):418-24. doi: 10.1177/00912709922007886.

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174.

Clin Pharmacol Ther. 1999 Mar;65(3):348-52. doi: 10.1016/S0009-9236(99)70114-1.

Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.

Eur J Clin Pharmacol. 1998 Feb;53(6):445-9. doi: 10.1007/s002280050405.

Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension.

Pharmacol Ther. 1997;74(2):181-94. doi: 10.1016/s0163-7258(97)82002-5.

Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension.

J Clin Pharmacol. 1996 May;36(5):403-8. doi: 10.1002/j.1552-4604.1996.tb05026.x.

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.

Clin Pharmacol Ther. 1995 Dec;58(6):641-9. doi: 10.1016/0009-9236(95)90020-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验